Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Ivermectin — macrocyclic lactone with antiparasitic profile
In short
Clears the body of parasites and is actively researched for supporting the immune system and cellular health.
Overview
Ivermectin is a mixture of 22,23-dihydroavermectin B1a (≥80%) and B1b (≤20%) — semi-synthetic macrocyclic lactones with broad-spectrum antiparasitic activity. The compound is poorly absorbed by mammalian cells due to P-glycoprotein efflux at the blood-brain barrier, providing the selectivity that underpins its safety profile.
Ivermectin selectively binds glutamate-gated chloride channels in invertebrate neurons and muscle cells, opening them and producing chloride influx that hyperpolarizes the cell. The result is paralysis. Mammalian glutamate-gated chloride channels do not exist in nervous tissue accessible at therapeutic doses, providing the species-selective therapeutic window.
Molecular information
Нежеланите събития при терапевтични дози обикновено са леки и саморазрешаващи се — замайване, гадене, преходна хипотония. Реакцията на Мацоти (възпаление на кожа/очи) може да възникне, когато високи паразитни товари умират бързо. Неврологични признаци при супратерапевтични дози са документирани; маржинът на безопасност при бозайници е широк поради P-гликопротеин-медиирано изключване от ЦНС.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about Ivermectin is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
